Caribbean News Now!

About Us Contact Us


Jump to your country or territory of interest

Advertise with us

Reach our daily visitors from around the Caribbean and throughout the world. Click here for rates and placements.


Submit news and opinion for publication


Click here to receive our daily regional news headlines by email.


Click here to browse our extensive archives going back to 2004

Also, for the convenience of our readers and the online community generally, we have reproduced the complete Caribbean Net News archives from 2004 to 2010 here.

Climate Change Watch

The Caribbean is especially vulnerable to rising sea levels brought about by global warming. Read the latest news and information here...


Follow Caribbean News Now on Twitter
Connect with Caribbean News Now on Linkedin

News from the Caribbean:

Back To Today's News

Cuban cancer medication registered in 28 countries
Published on March 26, 2014 Email To Friend    Print Version

HAVANA, Cuba (ACN) -- Nimotuzumab, a Cuban monoclonal antibody humanized to treat cancer, is registered in 28 countries, mainly in South America, Africa and Asia, in addition to Cuba.

Specialists at the Center of Molecular Immunology, an institution of the BioCubaFarma Business Group, said that the product has shown its effectiveness in various cases of malignant tumours.

Indicated for tumours in the head and neck in advanced stages, brain tumours and of the esophagus, Nimotuzumab is also used in other oncological ailments of the colon, rectum and liver, and in lung cancer among other locations.

The monoclonal antibody and its results will be the focus, on March 25-27, of the eighth global scientific meeting on Nimotuzumab -- Nimomeeting 2014.

With Havana's Convention Center as its venue, the forum will bring together over 200 experts from some 20 nations, as well as about 20 international biopharmaceutical companies interested in sharing experiences about the medication, the therapeutics of which are used in the medical specialties of oncology, oncopediatrics, radiotherapy, pediatrics and neurosurgery, among others.

Meanwhile, Cuba is trying to take its diabetic foot ulcer drug known as Heberprot-P into the European market.

Heberprot-P is a product based on human growth factor currently being administered in some 20 countries, mostly in Latin America.

According to the marketing director of the Havana-based Genetic Engineer and Biotechnology Center, Ernesto Lopez, the pre-clinical stage of the product, known in Europe as Epipropt, was carried out with good toxicological and safety results.

In Spain, with an estimate 40,000 patients needing the Cuban drug, tests were carried out with no negative toxic results. The product has been developed since 2012 for research studies in other European nations.

According to studies, amputation of lower limbs was reduced fourfold, with the surgical procedure in Europe currently costing over 50,000 Euros, and treatment of the condition some 20,000 Euros.

It is the amputation of lower limbs as a direct consequence of diabetic foot ulcer that the Cuban medication avoids with a period of treatment of only six to seven months.

Along with the therapeutic action on serious ulcers, the treatment has demonstrated a preventive nature in countries like Cuba, Venezuela, and Ecuador.
Reads: 2794

Click here to receive daily news headlines from Caribbean News Now!



No comments on this topic yet. Be the first one to submit a comment.


Send us your comments!  

Send us your comments on this article. All fields are required.

For your contribution to reach us, you must (a) provide a valid e-mail address and (b) click on the validation link that will be sent to the e-mail address you provide.  If the address is not valid or you don't click on the validation link, we will never see it!

Your Name:

Your Email:

(Validation required)

Enter Code

Please note that, if you are using an AT&T domain email address, e.g.,,, the verification email will likely not be delivered. This is outside of our control and the only remedy seems to be for readers to complain to AT&T

User comments posted on this website are the sole views and opinions of the comment author and are not representative of Caribbean News Now or its staff. Caribbean News Now accepts no liability and will not be held accountable for user comments.
Caribbean News Now reserves the right to remove, edit or censor any comments. Any content that is considered unsuitable, unlawful or offensive, includes personal details, advertises or promotes products, services or websites or repeats previous comments will not be approved.
Before posting, please refer to our Terms of Use and Privacy Policy.

The Caribbean Writer 2014

Other Headlines:

Regional Sports: